Literature DB >> 16023946

Quality assurance issues in radical prostatectomy.

H Van Poppel1, S F F Boulanger, S Joniau.   

Abstract

AIMS: Quality of surgery is a controversial issue and no studies are reporting on the standard of surgical quality in the treatment of urological cancer. The question is whether quality can be evaluated and whether there is a standard for a qualitatively well performed radical retropubic prostatectomy.
METHODS: We reviewed the literature on this topic. Data of four large studies based on Medicare claims and an EORTC report were analysed.
RESULTS: Two studies reflect hospital-volume rather than surgeon-volume. Two compared hospital-volume and surgeon-volume and in both studies there was no clear relationship between surgeon-volume and the parameters reviewed. Similarly, the EORTC study concluded that there is a variation in outcome that is not related to the caseload and proposed minimal quality standards for radical prostatectomy.
CONCLUSIONS: There is no clear relationship between surgeon-volume and surgical quality. Since radical prostatectomy is the standard treatment for the most frequent male malignancy and is offered to many patients that might never even suffer from the disease, the procedure must be performed with the highest guarantee of quality. Although, quality control of radical prostatectomy is feasible, its implementation will still require an enormous effort from the urological community.

Entities:  

Mesh:

Year:  2005        PMID: 16023946     DOI: 10.1016/j.ejso.2005.02.017

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  1 in total

1.  Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.

Authors:  Andrew J Vickers; Fernando J Bianco; Mithat Gonen; Angel M Cronin; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino
Journal:  Eur Urol       Date:  2008-01-14       Impact factor: 20.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.